secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001193125-23-268816
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia reports new Phase 1 data for NTLA-2001: median TTR reduction 91%, 55mg dose selected for Phase 3
--------------------------------------------------------------------------------

- Median serum TTR reduction of 91% and median residual TTR of 17 µg/mL at day 28 across 62 patients (doses ≥0.3 mg/kg).
- 29 patients with ≥12 months follow-up show sustained TTR reduction; no loss of activity over time.
- NTLA-2001 generally well tolerated; infusion-related reactions in 38% (mostly Grade 1-2); no dose-limiting toxicities.
- 55 mg fixed dose selected for global pivotal Phase 3 trial, expected to begin by year-end 2023; FDA IND clearance received.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312523268816/0001193125-23-268816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312523268816/d536006d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-268816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer